Neurocrine Biosciences

NBIXApproved

Founded in 1992, Neurocrine Biosciences has evolved from a research-focused biotech into a successful commercial company with over $1.5 billion in annual revenue. Their expertise in neuroscience drug development has produced breakthrough treatments like INGREZZA for tardive dyskinesia and a promising pipeline including programs for Parkinson's disease, schizophrenia, and endometriosis. The company combines strong commercial execution with continued innovation in CNS therapeutics.

Market Cap

$12.8B

Employees

800-1,000

Focus

Small Molecules

NBIX · Stock Price

USD 127.68+33.96 (+36.24%)

Historical price data

AI Company Overview

Technology Platform

Neuroscience-focused drug discovery and development platform with expertise in CNS therapeutics, leveraging deep understanding of neurological pathways and mechanisms including dopamine signaling and GABA modulation.

Pipeline Snapshot

87 drugs in pipeline, 22 in Phase 3

Drug	Indication	Stage
Valbenazine	Schizophrenia	Approved
Valbenazine + Placebo oral capsule	Tardive Dyskinesia (TD)	Approved
Valbenazine + Placebo oral capsule	Tardive Dyskinesia (TD)	Approved
Valbenazine	Schizophrenia	Approved
Valbenazine Oral Capsule	Tardive Dyskinesia	Approved

Funding History

Total raised: $42M

IPO$42MUndisclosedJul 25, 1996

FDA Approved Drugs

CRENESSITYNDADec 13, 2024

INGREZZA SPRINKLENDAApr 30, 2024

Opportunities

Significant growth opportunities exist through INGREZZA label expansions, multiple Phase 2/3 pipeline programs approaching potential approvals, and the ability to leverage commercial infrastructure for new product launches.

The company's strong financial position enables strategic acquisitions and partnerships to expand their neuroscience portfolio.

Risk Factors

Key risks include increasing competition in tardive dyskinesia from AUSTEDO and potential biosimilars, clinical trial execution risk across multiple development programs, and the inherent complexity and high failure rates in CNS drug development.

Patent expiration for INGREZZA and regulatory challenges represent additional concerns.

Competitive Landscape

Neurocrine competes with Teva Pharmaceuticals in tardive dyskinesia, where INGREZZA maintains market leadership over AUSTEDO. In the broader CNS space, they face competition from major pharmaceutical companies like Roche, Novartis, Biogen, and numerous biotech companies developing neurological and psychiatric treatments.

Publications

Patents

Pipeline

FDA Approvals